Objective: The ketogenic diet is clinically used to treat drug-resistant epilepsy. The diet treatment markedly increases ketone bodies (acetoacetate and b-hydroxybutyrate), which work as energy metabolites in the brain. Here, we investigated effects of acetoacetate on voltage-dependent Ca 2+ channels (VDCCs) in pyramidal cells of the hippocampus. We further explored an acetoacetate analog that inhibited VDCCs in pyramidal cells, reduced excitatory postsynaptic currents (EPSCs), and suppressed seizures in vivo. Methods: The effects of acetoacetate and its analogs on VDCCs and EPSCs were evaluated using patch-clamp recordings from CA1 pyramidal cells of mouse hippocampal slices. The in vivo effects of these reagents were also evaluated using a chronic seizure model induced by intrahippocampal injection of kainate. Results: Acetoacetate inhibited VDCCs in pyramidal cells of hippocampal slices, and reduced EPSCs in slices exhibiting epileptiform activity. More potent EPSC inhibitors were then explored by modifying the chemical structure of acetoacetate, and 2-phenylbutyrate was identified as an acetoacetate analog that inhibited VDCCs and EPSCs more potently. Although acetoacetate is known to inhibit vesicular glutamate transporters (VGLUTs), 2-phenylbutyrate did not inhibit VGLUTs, showing that 2-phenylbutyrate is an acetoacetate analog that preferably inhibits VDCCs. In addition, 2-phenylbutyrate markedly reduced EPSCs in slices exhibiting epileptiform activity, and suppressed hippocampal seizures in vivo in a mouse model of epilepsy. The in vivo antiseizure effects of 2-phenylbutyrate were more potent than those of acetoacetate. Finally, intraperitoneal 2-phenylbutyrate was delivered to the brain, and its brain concentration reached the level enough to reduce EPSCs. Significance: These results demonstrate that 2-phenylbutyrate is an acetoacetate analog that inhibits VDCCs and EPSCs in pyramidal cells, suppresses hippocampal seizures in vivo, and has brain penetration ability. Thus 2-phenylbutyrate provides a useful chemical structure as a lead compound to develop new antiseizure drugs originating from ketone bodies.
• The EPSC inhibition by acetoacetate and 2-phenylbutyrate was enhanced in slices exhibiting epileptiform activity
• Intraperitoneal 2-phenylbutyrate was delivered to the brain, and suppressed hippocampal seizures in vivo Epilepsy is a neurologic disorder that affects approximately 1% of the world's population; however, clinically used antiseizure drugs are not effective for one third of epileptic patients. 1 It has been known that the ketogenic diet is effective for some patients with drug-resistant epilepsy. 2 The ketogenic diet is a high-fat and low-carbohydrate diet, which produces ketone bodies (acetoacetate, b-hydroxybutyrate, and acetone) by the liver. The diet treatment was originally developed in the 1920s, and its modified version using medium-chain triglyceride was developed in the 1970s. 3 These exhibit comparable antiseizure effects for drug-resistant epilepsy. 4 However, despite the increasing attention, there are no antiseizure drugs that mimic these diet treatments. 5 It is important to elucidate the antiseizure mechanisms of the diet treatment, and to identify the antiseizure compounds based on the mechanisms.
The ketogenic diet changes two energy metabolites in the body: it increases ketone bodies and decreases glucose. 6 These two metabolic changes lead to neural inhibition and antiseizure actions (reviewed in Lutas and Yellen 7 ) . Ketone bodies are known to open ATP-sensitive K + channels (K ATP channels), and reduce the firing rate of neurons. 8, 9 In addition, ketone bodies inhibit vesicular glutamate transporters (VGLUTs), reduce miniature excitatory postsynaptic currents (EPSCs) and suppress seizures in vivo. 10 In terms of decreases in glucose, it has long been known that electrical activities in neurons of some brain regions are modulated by changes in extracellular glucose, called glucose-responsive and glucose-sensitive neurons (reviewed in Levin et al. 11 ). Although severe reductions in glucose elicit seizures, its moderate reductions as observed in the ketogenic diet can suppress seizures. The ketogenic diet has been shown to suppress seizures via adenosine A 1 receptors, 12 which is probably due to decreases in glucose. 13 Reductions in glucose metabolism suppress seizures in vivo, 14, 15 and this is partially via K ATP channels. 15 Furthermore, glucose in astrocytes is released to neurons as lactate, which maintain neuronal activities 16, 17 : the ketogenic diet reduces the release of lactate, which results in neuronal hyperpolarization and the suppression of seizures. 17 It is noteworthy that the ketone bodies themselves are endogenous antiseizure metabolites. [7] [8] [9] [10] However, previous findings on the neuronal actions of ketone bodies are insufficient to fully account for the antiseizure actions of the ketogenic diet. In brain slices, the opening of K ATP channels by ketone bodies reduces the firing rate of neurons by only 10%. 8 Furthermore, the inhibition of VGLUTs by ketone bodies reduces the quantal size of vesicular glutamate by only 25%. 10 In the present study we therefore explored other targets of ketone bodies, and focused on voltage-dependent Ca 2+ channels (VDCCs) because they critically regulate synaptic transmission in the central nervous system (CNS). VDCCs in CNS neurons are known to be regulated by a variety of extracellular factors, such as neurotransmitters, 18, 19 metabolites, 20, 21 and polypeptides. 22, 23 A recent study has also shown that b-hydroxybutyrate inhibits VDCCs in peripheral nervous system (PNS) neurons. 24 Here we showed that acetoacetate, a ketone body, inhibited VDCCs in pyramidal cells of the hippocampus, and suppressed EPSCs in brain slices exhibiting epileptiform activity. We further modified the chemical structure of acetoacetate, and identified a compound that potently inhibited VDCCs and EPSCs in slices and reduced hippocampal seizures in vivo.
Methods

Animals
Experiments were performed using ICR mice of both sexes (3-to 7-week-old) for in vitro recordings, and male ICR mice (6-to 7-week-old) for in vivo recordings and brain penetration experiments, except where otherwise noted. Typically, 3-to 4-week-old mice were used for in vitro recordings because slice viability was better in these ages. For in vivo recordings, older mice (6-to 7-week-old) were used because previous studies have used adult mice to induce chronic seizure by intrahippocampal kainate. 17, 25 All animal experiments were approved and conducted in accordance with the Animal Research Committee at Okayama University.
Slice preparation and patch-clamp recordings in vitro
Hippocampal slices obtained from mice were perfused in oxygenated artificial cerebrospinal fluid (ACSF), patchclamp recordings were made from CA1 pyramidal cells of the hippocampal slices, and effects of acetoacetate and its analogs on voltage-dependent Ca 2+ currents and evoked EPSCs were examined. The details are provided in Data S1.
Chronic seizure model in vivo
Paroxysmal discharges and high-voltage spikes in the hippocampus were recorded from the chronic seizure model induced by intrahippocampal kainate, according to previous studies. 17, 25 Acetoacetate and its analog, 2-phenylbutyrate, were intraperitoneally injected to this kainate model, and changes in the epileptiform activities were examined in vivo. The details are provided in Data S1.
Brain concentration of 2-phenylbutyrate in vivo
2-Phenylbutyrate was intraperitoneally injected in vivo, and then its brain concentration was measured using highperformance liquid chromatography (HPLC) analyses. The details are provided in Data S1.
VGLUT transport assay
VGLUT activities were evaluated by measuring the uptake of glutamate into proteoliposomes containing purified VGLUT2 as described previously. 10 The details are provided in Data S1.
Chemical reagents
Acetoacetate and its analogs were used as sodium salts. See Data S1 for details.
Data analysis
Electrophysiologic data were analyzed using Igor Pro 6 (Wavemetrics). Summarized data were reported as mean AE standard error of the mean (SEM). Statistical significance was evaluated by the Student's t-test for two group comparisons, by one-way analysis of variance (ANOVA) followed by Tukey's test for multiple group comparisons, and by one-way repeated-measures ANOVA followed by Dunnett's test for comparing data over time, using SigmaPlot 12 (Systat Software).
Results
Acetoacetate inhibits VDCCs in hippocampal pyramidal cells
The ketogenic diet increases plasma ketone bodies at 8 mM in rodents in vivo 26 ; therefore, the neuronal actions of ketone bodies have been studied at 2-10 mM in brain slices. [8] [9] [10] Using slice patch-clamp techniques, we measured voltage-dependent Ca 2+ currents in pyramidal cells of the hippocampal CA1 region, and examined the effects of 10 mM acetoacetate on the Ca 2+ currents. Whole-cell recordings were obtained from neurons in acute slice preparations, [27] [28] [29] because neurons in brain slices are surrounded by physiologic extracellular environments. Ca 2+ currents were isolated by blocking Na + and K + channels (see Data S1 for details). Voltage-dependent Ca 2+ currents under wholecell recordings are known to cause time-dependent decreases in amplitude, referred to as rundown. 29, 30 In our recordings, a 15-min perfusion with the extracellular solution (ACSF) induced a small rundown in peak Ca 2+ currents (Fig. S1A,B) , whereas a 15-min perfusion with ACSF including 10 mM sodium acetoacetate markedly reduced peak Ca 2+ currents (Fig. S1C,D) . Because the largest peak Ca 2+ currents were evoked by the voltage step to À20 mV (Fig. S1) , we then compared the amplitudes of Ca 2+ currents evoked by the step to À20 mV in the absence ( Fig. 1A; i.e., rundown effects) or presence (Fig. 1B) Fig. 1C ; 57.0 AE 5.6% of the baseline; n = 8) than by the rundown (Control in Fig. 1C ; 83.7 AE 3.9% of the baseline; n = 7) (p = 0.002, unpaired t-test). Sustained Ca 2+ currents were not changed by acetoacetate ( Fig. 1D ; p = 0.28, unpaired ttest). The reduction in peak Ca 2+ currents by sodium acetoacetate (Fig. 1C) was not due to its extracellular osmotic changes, because extracellular osmolarity was adjusted by replacing 10 mM NaCl in ACSF with 10 mM sodium acetoacetate. This reduction was also not due to the decrease in Cl -ions in ACSF elicited by the osmolarity adjustment, because replacing 10 mM NaCl in ACSF with 10 mM sodium methanesulfonate, a nonfunctional organic anion used as the intracellular solution, only weakly reduced peak Ca 2+ currents (79.2 AE 4.1% of the baseline; n = 5), which was similar to the rundown effect (83.7 AE 3.9% of the baseline; n = 7). These results show that acetoacetate inhibits VDCCs in pyramidal cells of the hippocampal CA1 region.
Acetoacetate more potently inhibits EPSCs in epileptiform activity
Inhibition of Ca 2+ entry through VDCCs reduces EPSCs, and increases the paired-pulse ratio (PPR) of EPSCs. 31 Because acetoacetate inhibited Ca 2+ currents (Fig. 1) , we then examined whether acetoacetate also reduced EPSCs and increased the PPR of EPSCs. EPSCs in CA1 pyramidal cells were evoked by stimulating Schaffer collateral fibers at the stratum radiatum. Contrary to our expectations, 10 mM acetoacetate hardly changed the EPSC amplitude and the PPR of EPSCs (Normal in Fig. 2B ). Because the Ca 2+ currents shown in Figure 1 were recorded in the extracellular presence of K + channel blockers (TEA-Cl and CsCl) in order to isolate Ca 2+ currents, we then examined the effects of acetoacetate on EPSCs in the presence of these K + channel blockers. In current-clamp recordings, CA1 pyramidal cells were silent in normal slices (Normal in Fig. 2A ), but exhibited epileptiform bursting in the presence of K + channel blockers (5 mM TEA-Cl and 1 mM CsCl) (Epileptiform in Fig. 2A ) (n = 7). Epileptiform EPSC barrages were observed in voltage-clamp recordings ( Fig. S2 ; n = 6). In this epileptiform activity, 10 mM acetoacetate markedly reduced the EPSC amplitude (first EPSC in Epileptiform of Fig. 2B ) and increased the PPR of EPSCs (Epileptiform in Fig. 2B ). Quantitatively, acetoacetate more potently reduced the EPSC amplitude in epileptiform activity (Epileptiform in Fig. 2C ,D; 50.5 AE 4.8% of the baseline; n = 8) than in the normal state (Normal in Fig. 2C ,D; 88.5 AE 9.6% of the baseline; n = 8) (p = 0.005, unpaired ttest). Furthermore, acetoacetate did not change the PPR of EPSCs in the normal state (Normal in Fig. 2E ; n = 8; p = 0.36, paired t-test), but significantly increased their PPR in epileptiform activity (Epileptiform in Fig. 2E ; n = 8; p = 0.044, paired t-test), suggesting that the EPSC inhibition is mediated by VDCCs. These results show that acetoacetate more potently inhibits EPSCs in epileptiform activity.
2-Phenylbutyrate is a potent EPSC inhibitor originating from acetoacetate
We then explored more potent EPSC inhibitors than acetoacetate by modifying its chemical structure. As expected in Figure 2B , 10 mM acetoacetate (AA) had a little effect on EPSC amplitudes in the normal state (AA in Fig. 3A ,B; 91.2 AE 6.5% of the baseline; n = 6). b-Hydroxybutyrate (b-HB), another ketone body, also had a little effect on EPSC amplitudes (b-HB in Fig. 3B and Fig. S3A ; 93.5 AE 6.1% of the baseline; n = 5). However, the remarkable EPSC inhibition was observed in a-ketobutyrate (a-KB), in which the carbonyl group of acetoacetate was transferred from the b-position to the a-position (a-KB in Fig. 3B and Fig. S3B ; 65.5 AE 6.2% of the baseline; n = 7). The EPSC inhibition was also observed in benzoylformate (BF), in which the carbon chain of a-KB was substituted with a phenyl group (BF in Fig. 3B ,C; 55.0 AE 4.9% of the baseline; n = 8). We then changed the carbonyl group of BF at the a-position to a number of functional groups, and examined their effects on the EPSC inhibition ( Fig. 3D ,E; Figs. S4 and S5 for details). Our screening at the level of EPSCs revealed that, among the BF analogs shown in the left panel of Figure 3D , three BF analogs (CPA, BPA, and PB in Fig. 3D ) potently reduced the EPSC amplitude. Especially, 2-phenylbutyrate (PB) inhibited the EPSC amplitude Under stable whole-cell recordings, neurons were perfused for 15 min with ACSF including Na + and K + channel blockers, and baseline Ca 2+ currents were then obtained (black in A and B). Neurons were further perfused for 15 min with ACSF including no reagents (A) or acetoacetate (B), and Ca 2+ currents were obtained again (gray in A, and blue in B). Ca 2+ currents were elicited by voltage steps from À60 mV to 0 mV with 10-mV increments (see Fig. S1 ), and those elicited by the step to À20 mV are shown in this figure. (C,D) A summary of the data from A and B (n = 7 for Control, n = 8 for Acetoacetate), showing changes in Ca 2+ currents at the peak (C) and steady-state (D). Changes in Ca 2+ currents elicited by no reagents as the control (A) or acetoacetate (B) are summarized as gray or blue columns, respectively. Ca 2+ currents on the vertical axes are normalized by the amplitudes of baseline Ca 2+ currents. Data are mean AE SEM. **p < 0.01; NS, not significant from the data of Control (unpaired t-test). (E) The concentration-dependent inhibition of peak Ca 2+ currents by acetoacetate (n = 3-8). Data are mean AE SEM. Epilepsia ILAE EPSCs were evoked every 20 s by paired-pulse stimuli (50-msec interval) at the stratum radiatum in 100 lM picrotoxin, and averaged every 1 min. Stimulus artifacts were truncated for clarity. Paired-pulse responses scaled to first EPSCs are shown in Overlay. Note that acetoacetate did not change the PPR in the normal state (Normal), but increased it in epileptiform activity (Epileptiform). (C,D) A summary of the data from B (n = 8 for Normal, n = 8 for Epileptiform), showing the time courses of EPSC amplitudes (C) and EPSC reductions in the last 3 min of the 15-min treatment with acetoacetate (D). EPSC changes in the normal state (black) and in epileptiform activity (red) are shown. EPSC amplitudes (measured from the first EPSCs) were normalized by those of baseline EPSCs. In C, acetoacetate was applied at the underlined section. Data are mean AE SEM. **p < 0.01 from the data of Normal in D (unpaired t-test). (E) A summary of the data from B, showing the PPRs of EPSCs in the normal state (left) (n = 8) and in epileptiform activity (right, with red shading) (n = 8). The PPRs of baseline EPSCs (black) and of EPSCs in the last 3 min of the 15-min treatment with acetoacetate (blue) are shown. Data are mean AE SEM. *p < 0.05; NS, not significant from the data of Baseline (paired t-test). Epilepsia ILAE even at a lower concentration of 1 mM (Fig. 3E and  Fig. S6C ). In addition, 2-phenylbutyrate consisted of only three elements (carbon, hydrogen, and oxygen), whereas the other two BF analogs (CPA and BPA in Fig. 3D ) included halogens. Based on these results, we studied 2-phenylbutyrate in more detail as a potent EPSC inhibitor originating from the chemical structure of acetoacetate.
2-Phenylbutyrate inhibits VDCCs
Because acetoacetate inhibited VDCCs (Fig. 1) , we examined whether 2-phenylbutyrate also inhibited VDCCs. As was the case with acetoacetate (Fig. 4A) , a 15-min perfusion with 10 mM 2-phenylbutyrate also reduced peak Ca 2+ currents (Fig. 4B and Fig. S7 ). Furthermore, this reduction in peak Ca 2+ currents by 2-phenylbutyrate (PB in Fig. 4C ; 27.6 AE 5.2% of the baseline; n = 7) was significantly more potent than that by acetoacetate (AA in Fig. 4C ; 57.0 AE 5.6% of the baseline; n = 8) (p = 0.002, unpaired ttest). Sustained Ca 2+ currents were not changed by 2-phenylbutyrate ( Fig. 4D ; p = 0.81, unpaired t-test). Consistent with this reduction in Ca 2+ currents, 3 mM 2-phenylbutyrate significantly increased the PPR of EPSCs (Fig. 4E,F ; n = 4; p = 0.046, paired t-test). These results show that 2-phenylbutyrate also inhibits VDCCs and reduces EPSCs in pyramidal cells.
A previous study has shown that acetoacetate inhibits VGLUTs. 10 Because VGLUTs also regulate EPSCs, we examined whether 2-phenylbutyrate acted on VGLUTs. Based on the previous study, 10 VGLUT activities were evaluated by measuring the uptake of glutamate into proteoliposomes with purified VGLUT2. In this assay system, valinomycin (Val) evokes glutamate uptake via VGLUT (compare ÀVal vs. +Val in Fig. 4G ), and the Val-evoked glutamate uptake (i.e., VGLUT activities) is inhibited by acetoacetate with an 50% inhibitory concentration (IC 50 ) of 200 lM. 10 However, we found that VGLUT activities were only weakly inhibited by the acetoacetate analog BF (2 mM; the right column of BF in Fig. 4G ) (see Fig. 3B for the chemical structures). Moreover, VGLUT activities were not changed by the benzoylformate analogs (BPA and PB in Fig. 4G) , showing that 2-phenylbutyrate did not inhibit VGLUTs.
Taken together, acetoacetate inhibits VGLUTs and VDCCs, whereas 2-phenylbutyrate potently inhibits VDCCs but has no effects on VGLUTs. These results suggest that 2-phenylbutyrate is an acetoacetate analog in which the ability of acetoacetate to inhibit VDCCs is selectively enhanced.
2-Phenylbutyrate more potently inhibits EPSCs in epileptiform activity
Because acetoacetate inhibited EPSCs in slices exhibiting epileptiform activity (Fig. 2) , we then examined the effects of 2-phenylbutyrate on EPSCs in epileptiform activity. Epileptiform activity was elicited in the same manner as in Figure 2A . We found that, although 10 mM 2-phenylbutyrate reduced the EPSC amplitude in the normal state (Normal in Fig. S8A ), it completely inhibited EPSCs in epileptiform activity (Epileptiform in Fig. S8A ). Quantitatively, this EPSC reduction in epileptiform activity (Epileptiform in Fig. S8B,C; 8. 3 AE 2.1% of the baseline; n = 5) was significantly greater than that in the normal state (Normal in Fig. S8B,C; 28.7 AE 4.9% of the baseline; n = 9) (p = 0.003, unpaired t-test). These results show that, similar to acetoacetate, 2-phenylbutyrate also more potently inhibits EPSCs in epileptiform activity.
2-Phenylbutyrate suppresses chronic seizures in mice in vivo
We finally examined whether 2-phenylbutyrate could suppress chronic seizures in vivo using a kainate model. We selected this kainate model because it has been widely used as a chronic seizure model. 17, 25, 32 Previous studies have shown that no epileptiform activities are observed within 2 weeks after the intrahippocampal injection of kainate, but then epileptiform activities (high-voltage spikes and paroxysmal discharges) emerge in the kainate-injected hippocampus. 17, 25, 32 It also exhibits abnormal morphology similar to hippocampal sclerosis in humans. 25 In contrast, no epileptiform activities have been observed in the hippocampus of sham-operated mice. 17, 25 To generate this kainate model, a small amount of kainate was directly injected into the hippocampus, and recording electrodes were then placed at the injected site for local field potential (LFP) recordings (Fig. S9A) . Spontaneous highvoltage spikes, characterized as isolated spikes or clusters of several spikes, were observed 2 weeks after the kainate injection (Fig. S9B) . Spontaneous paroxysmal discharges, characterized as high-frequency rhythmic activities, were then observed 3 weeks after the kainate injection (Fig. S9C) . These characteristics were consistent with previous studies. 17, 25, 32 Using this kainate model, we examined the effects of acetoacetate and 2-phenylbutyrate on hippocampal paroxysmal discharges in vivo. These reagents were intraperitoneally (i.p.) injected at a dose of 500 mg/kg, because acetoacetate has been reported to exert antiseizure effects at 7.3 mmol/kg (approximately 730 mg/kg) in audiogenic seizure-susceptible mice. 33 In this kainate model, spontaneous paroxysmal discharges were not changed by an intraperitoneal injection of saline as a control (Fig. 5A) , but suppressed by acetoacetate (500 mg/kg, i.p.; Fig. 5B ), and markedly suppressed by 2-phenylbutyrate (500 mg/ kg, i.p.; Fig. 5C ) (see Fig. 5D ,F for the time course of changes in paroxysmal discharges). Quantitatively, the number of paroxysmal discharges was significantly changed by acetoacetate and 2-phenylbutyrate ( Fig. 5E ; p < 0.001 by one-way ANOVA; n = 10 in each group). The number of paroxysmal discharges was not changed by saline (Saline in Fig. 5E ; 105.7 AE 7.1% of the , and the time course of EPSC amplitudes (right) (n = 9). In A-E, EPSCs in CA1 pyramidal cells were evoked every 15 s by stimulating the stratum radiatum in 100 lM picrotoxin, and then averaged every 1 min. The amplitudes were normalized by those of baseline EPSCs. In A, C, and E, stimulus artifacts of EPSC traces were truncated for clarity. Data are mean AE SEM. Epilepsia ILAE F) A summary of the data from A-C, showing the number of paroxysmal discharges (D) and total duration of paroxysmal discharges (F) changed by the intraperitoneal injection of saline (black), acetoacetate (blue), or 2-phenylbutyrate (green) (n = 10 in each group). Changes in the number of paroxysmal discharges (D) and total duration of paroxysmal discharges (F) are shown in every 30-min time frame. Baseline events were calculated from 30-min recordings before the injection. Data are mean AE SEM. **p < 0.01 from the baseline (one-way repeated measures ANOVA followed by Dunnett's test). (E,G) The number of paroxysmal discharges (E) and total duration of paroxysmal discharges (G) for 0-30 min after the intraperitoneal injection of saline (gray columns), acetoacetate (blue columns), or 2-phenylbutyrate (green columns) (n = 10 in each group). The number (E) and total duration (G) of paroxysmal discharges on the vertical axes were normalized by those for 30 min before the injection (Baseline). The three reagents were administrated to the same mouse. Data are mean AE SEM. **p < 0.01; *p < 0.05 (one-way ANOVA followed by Tukey's test). Epilepsia ILAE Epilepsia, 58 (5):845-857, 2017 doi: 10.1111/epi.13718 baseline), but reduced by acetoacetate (AA in Fig. 5E ; 64.2 AE 13.1% of the baseline) (p = 0.010 from Saline, Tukey's test), and further reduced by 2-phenylbutyrate (PB in Fig. 5E ; 10.2 AE 5.9% of the baseline) (p < 0.001 from AA, Tukey's test). Similar results were observed about the total duration of paroxysmal discharges (Fig. 5G) . These results show that 2-phenylbutyrate suppresses seizures in vivo in a mouse model of epilepsy.
Antiseizure effects of 2-phenylbutyrate and its brain concentrations in vivo
We then examined that this suppression of seizures in vivo (Fig. 5 ) was attributable to central action of 2-phenylbutyrate. As with paroxysmal discharges, high-voltage spikes in this kainate model were not changed by intraperitoneal injections of saline (Fig. 6A,B) but reduced by 2-phenylbutyrate (500 mg/kg, i.p.; Fig. 6C,D) . The high-voltage spikes were not reduced, rather increased, by 2-phenylbutyrate at a dose of 100 mg/kg i.p. (Fig. 6E) , indicating that the dose of 500 mg/kg is required to suppress seizures in vivo. Using HPLC analyses, we found that 2-phenylbutyrate injected intraperitoneally was delivered to the brain in a dose-dependent manner (Fig. 6F) . It is important to note that although 2-phenylbutyrate reduced EPSCs at ≥1 mM in vitro (Fig. S8D ), 2-phenylbutyrate at 100 mg/ kg, i.p., could not increase its brain concentration to 1 mM ( Fig. 6F ; 0.35 AE 0.01 mM; n = 6), whereas 2-phenylbutyrate at 500 mg/kg, i.p., increased its brain concentration to 2.08 AE 0.16 mM ( Fig. 6F ; n = 7). Thus the brain concentration to suppress seizures in vivo is comparable to the concentration to reduce EPSCs in neurons. These results suggest that intraperitoneal 2-phenylbutyrate is delivered to the brain, in which EPSCs are reduced and then seizures are suppressed in vivo.
Sex differences in antiseizure effects of 2-phenylbutyrate
These antiseizure effects in vivo (Figs. 5 and 6) have been examined using male mice, and we then examined the antiseizure effects in age-matched female mice. Saline or 2-phenylbutyrate was injected intraperitoneally to the kainate model of female mice, away from the estrous stage (see Data S1 for details). As with male mice, high-voltage spikes in female kainate model were not changed by intraperitoneal injections of saline (Fig. S10A ) but reduced by 2-phenylbutyrate (500 mg/kg, i.p.; Fig. S10B ) (n = 6 in each group). This reduction in high-voltage spikes in female mice was comparable to that in male mice (see Fig. 6D ), and these reductions at 0-30 min after the injection did not differ significantly between male (21.9 AE 5.9% of the baseline, n = 6) and female mice (38.5 AE 15.4% of the baseline, n = 6) ( Fig. S10C ; p = 0.35, unpaired t-test). These results show no sex differences in antiseizure effects of 2-phenylbutyrate.
Discussion
In the present study, we found that acetoacetate inhibited VDCCs in hippocampal pyramidal cells (Fig. 1) . The actions of ketone bodies (acetoacetate and b-hydroxybutyrate) on CNS neurons have recently received increasing attention due to the antiseizure effects of the ketogenic diet. 7 Ketone bodies reduce the firing rate of neurons via K ATP channels. 8, 9 Ketone bodies inhibit VGLUTs, reduce miniature EPSCs, and suppress seizures. 10 We also found that acetoacetate inhibited VDCCs and EPSCs in pyramidal cells, and suppressed hippocampal seizures in vivo. This is an important finding to account for the antiseizure actions of the ketogenic diet.
Previous studies have shown that VDCCs are regulated by extracellular factors. Neurotransmitters such as glutamate regulate VDCCs via metabotropic receptors. 18, 19 VDCCs are also regulated by metabolites such as vitamin D, 20, 21 and secretory polypeptides such as amyloid b. 22, 23 In the present study, we demonstrated that acetoacetate regulated VDCCs (Fig. 1) ; however, the underlying mechanism remains unclear. Although b-hydroxybutyrate is known to regulate N-type VDCCs via free fatty acid receptor 3 (FFA3) in sympathetic ganglionic neurons of the PNS, 24 few FFA3 receptors are expressed in the brain. 34, 35 It will be necessary to elucidate what kinds of receptors and which types of VDCCs are involved in the acetoacetate-induced inhibition of VDCCs in CNS neurons.
The present study also identified 2-phenylbutyrate as a more potent VDCC inhibitor originating from the chemical structure of acetoacetate. 2-Phenylbutyrate inhibited VDCCs and EPSCs in brain slices (Figs. 3 and 4) , and suppressed seizures in vivo (Fig. 5) . Furthermore, the EPSC inhibition by 2-phenylbutyrate was enhanced in slices exhibiting epileptiform activity (Fig. S8 ). These neural actions by 2-phenylbutyrate are consistent with those by acetoacetate (Figs. 1, 2 and 5) . Notably, 2-phenylbutyrate inhibited VDCCs more potently than acetoacetate, whereas 2-phenylbutyrate did not inhibit VGLUTs, unlike acetoacetate. Thus 2-phenylbutyrate is suggested to be an acetoacetate analog in which the ability of acetoacetate to inhibit VDCCs is selectively enhanced.
Our success in identifying 2-phenylbutyrate as an antiseizure compound in vivo is largely attributable to screening at the level of EPSCs using brain slices (Fig. 3) . Compound screening is generally performed using cultured cells that forcibly express VDCCs only: this is high-throughput, but devoid of endogenous components in the brain (e.g., signaling pathways from receptors to VDCCs, and neuromodulators released from surrounding cells). In contrast, our screening using brain slices included more endogenous components, which may lead to the identification of 2-phenylbutyrate as a suppressor of seizures in vivo. An issue to be addressed is the effective concentration of 2-phenylbutyrate in vivo (500 mg/kg, Figs. 5 and 6), which is 10-100 fold higher than that of clinically used drugs (5-250 mg/kg in mice 36 ). In addition, 2-phenylbutyrate is unlikely to be selective for VDCCs in vivo and likely to have off-targets other than VDCCs, because seizures were rather increased by 2-phenylbutyrate at 100 mg/kg (Fig. 6E) . More potent and selective compounds will be required to develop therapeutic drugs, which could be achieved by modifying the chemical structure of 2-phenylbutyrate as a lead compound.
Based on several dose-response studies (Fig. 6E ,F, and Fig. S8D ), this in vivo antiseizure action at a dose of 500 mg/kg, i.p., is probably mediated by VDCC inhibition and EPSC reduction in the brain. Pharmacologic studies in vivo (Fig. 6E ) revealed that antiseizure actions by 2-phenylbutyrate were observed at 500 mg/kg, but not at 100 mg/kg. Brain penetration studies (Fig. 6F) revealed that 2-phenylbutyrate at intraperitoneal doses of 100 and 500 mg/kg increased its brain concentrations to 0.35 and 2.08 mM, respectively. It is notable that 2-phenylbutyrate reduced EPSCs in neurons at ≥1 mM in vitro (Fig. S8D) . Considering that this EPSC reduction was due to VDCC inhibition (Fig. 4E,F) , intraperitoneal 2-phenylbutyrate is suggested to be delivered to the brain, inhibit VDCCs and EPSCs in neurons, and then suppress seizures in vivo.
Of interest, we found that the EPSC inhibition by acetoacetate and 2-phenylbutyrate was enhanced in slices exhibiting epileptiform activity ( Fig. 2 and Fig. S8 ). This result suggests that these compounds preferentially suppress excess neural activities in a focus of seizures. Although the underlying mechanism currently remains unclear, it is plausible that the seizure-enhanced inhibition of EPSCs is caused by factors changing in epileptiform activity. One possibility of the factors is the extracellular environment. In epileptiform activity, glutamate and other amino acids are released into extracellular spaces. 37 Inhibition of VDCCs by acetoacetate and 2-phenylbutyrate may be further facilitated by neurotransmitters released in epileptiform activity. Further studies will be required to elucidate the mechanisms by which acetoacetate and 2-phenylbutyrate more potently inhibit EPSCs in epileptiform activity.
Some antiseizure drugs acting on VDCCs have already been developed and clinically used. 29, 30, [38] [39] [40] Gabapentin and pregabalin are new antiseizure drugs that mainly target VDCCs. 38 These antiseizure drugs reduce voltage-dependent Ca 2+ currents, and reduce EPSC amplitudes in CNS neurons. 39, 40 Other antiseizure drugs, levetiracetam and topiramate, also reduce voltage-dependent Ca 2+ currents in neurons, 29, 30 although these antiseizure drugs mainly have different target molecules. 38 Thus, these antiseizure drugs have the same target molecule as 2-phenylbutyrate. However, 2-phenylbutyrate is clearly distinguishable from these antiseizure drugs because it originates from ketone bodies, namely, its chemical structure is unique as an antiseizure drug in terms of carboxylic acids with benzene rings. Antiseizure drugs originating from the ketogenic diet treatment may be developed by further modifying the chemical structure of 2-phenylbutyrate to more potently and selectively act on VDCCs.
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